Citation Impact
Citing Papers
Randomized Trial of Denosumab in Patients Receiving Adjuvant Aromatase Inhibitors for Nonmetastatic Breast Cancer
2008
Zoledronic Acid Has Differential Antitumor Activity in the Pre- and Postmenopausal Bone Microenvironment In Vivo
2014
Cancer Treatment–Induced Bone Loss in Breast and Prostate Cancer
2008
Multiphoton Phosphorescence Quenching Microscopy Reveals Kinetics of Tumor Oxygenation during Antiangiogenesis and Angiotensin Signaling Inhibition
2022 StandoutNobel
Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer
2019 Standout
Hypoxia-inducible factors and RAB22A mediate formation of microvesicles that stimulate breast cancer invasion and metastasis
2014 StandoutNobel
Cancer–stromal cell interactions mediated by hypoxia-inducible factors promote angiogenesis, lymphangiogenesis, and metastasis
2012 StandoutNobel
Breast cancer
2019 Standout
Overexpression of hypoxia-inducible factor 1alpha is associated with an unfavorable prognosis in lymph node-positive breast cancer.
2002
Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes
2012 Standout
Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial
2012
American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer
2007 Standout
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials
2011 Standout
Triple-Negative Breast Cancer
2010 Standout
Overexpression of Id‐1 is associated with poor clinical outcome in node negative breast cancer
2003
Gene Expression and Benefit of Chemotherapy in Women With Node-Negative, Estrogen Receptor–Positive Breast Cancer
2006 Standout
Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results
2012
30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study
2005
Breast cancer
2016 Standout
Cancer nanomedicine: progress, challenges and opportunities
2016 Standout
Targeting HIF-1 for cancer therapy
2003 StandoutNobel
Contribution of platelets to tumour metastasis
2011 Standout
St. Gallen/Vienna 2019: A Brief Summary of the Consensus Discussion on the Optimal Primary Breast Cancer Treatment
2019
The European Society of Breast Cancer Specialists recommendations for the management of young women with breast cancer
2012
TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine ± trastuzumab
2011
Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer
2005 Standout
Understanding the tumor immune microenvironment (TIME) for effective therapy
2018 Standout
Preoperative thrombocytosis predicts poor survival in patients with glioblastoma
2007
Nanoparticle therapeutics: an emerging treatment modality for cancer
2008 Standout
The biology and function of fibroblasts in cancer
2016 Standout
Second international consensus guidelines for breast cancer in young women (BCY2)
2016
Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers
2008 Standout
New insights into the mechanisms of epithelial–mesenchymal transition and implications for cancer
2018 Standout
Tumor-Associated Macrophages: From Mechanisms to Therapy
2014 Standout
Osteoporosis: now and the future
2011 Standout
The landscape of long noncoding RNAs in the human transcriptome
2015 Standout
Guidance for the management of breast cancer treatment-induced bone loss: A consensus position statement from a UK Expert Group
2008
The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2− breast cancer patients
2013
Hypoxia-inducible factor–dependent breast cancer–mesenchymal stem cell bidirectional signaling promotes metastasis
2012 StandoutNobel
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2010 Standout
Single-agent treatment with pegylated liposomal doxorubicin for metastatic breast cancer
2008
Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial
2014
Trastuzumab — Mechanism of Action and Use in Clinical Practice
2007 Standout
p21 in cancer: intricate networks and multiple activities
2009 Standout
Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years
2016
Microvesicles derived from activated platelets induce metastasis and angiogenesis in lung cancer
2004
Effective inhibition of aromatase inhibitor‐associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole
2008
Bone health in cancer patients: ESMO Clinical Practice Guidelines
2014
Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study
2010
Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape
2012
Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer
2013 Standout
Role of bisphosphonates in postmenopausal women with breast cancer
2013
Emerging Biological Principles of Metastasis
2017 Standout
Membrane-derived microvesicles: important and underappreciated mediators of cell-to-cell communication
2006
Adjuvant Chemotherapy With Gemcitabine vs Observation in Patients Undergoing Curative-Intent Resection of Pancreatic Cancer
2007 Standout
Gene-Expression Signatures in Breast Cancer
2009
The immune contexture in human tumours: impact on clinical outcome
2012 Standout
Microenvironmental regulation of metastasis
2008 Standout
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
2010 Standout
A randomized placebo-controlled study of tamoxifen after adjuvant chemotherapy in premenopausal women with early breast cancer (National Cancer Institute of Canada—Clinical Trials Group Trial, MA.12)
2009
Late Recurrences in Early Breast Cancer: For Whom and How Long Is Endocrine Therapy Beneficial?
2014
Direct and indirect anticancer activity of bisphosphonates: A brief review of published literature
2011
Glypican-1 identifies cancer exosomes and detects early pancreatic cancer
2015 StandoutNature
Hypoxia inducible factor-1α correlates with VEGF-C expression and lymphangiogenesis in breast cancer
2006
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial
2010
The tumour-induced systemic environment as a critical regulator of cancer progression and metastasis
2014
Metastatic colonization by circulating tumour cells
2016 StandoutNature
Effects of Bone-Targeted Agents on Cancer Progression and Mortality
2012
Extended adjuvant endocrine therapy in hormone-receptor positive early breast cancer: Current and future evidence
2015
Microenvironmental regulation of tumor progression and metastasis
2013 Standout
Platelet–cancer interactions: mechanisms and pharmacology of tumour cell‐induced platelet aggregation
2004
Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics
2009 StandoutNobel
First international consensus guidelines for breast cancer in young women (BCY1)
2014
Novel approaches to target the microenvironment of bone metastasis
2021
Systematic review of LHRH agonists for the adjuvant treatment of early breast cancer
2005
Extracellular vesicles: Exosomes, microvesicles, and friends
2013 Standout
Zoledronic Acid Prevents Bone Loss in Premenopausal Women Undergoing Adjuvant Chemotherapy for Early-Stage Breast Cancer
2008
Trastuzumab in the management of early and advanced stage breast cancer.
2007
Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials
2007
American Society of Clinical Oncology Clinical Practice Guideline: Update on Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer
2010
Platelets at the interface of thrombosis, inflammation, and cancer
2015
American Society of Clinical Oncology Recommendations on Fertility Preservation in Cancer Patients
2006 Standout
Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: A Cancer Care Ontario and American Society of Clinical Oncology Clinical Practice Guideline
2017
Breast Cancer Treatment
2019 Standout
Effect of Endocrine Therapies on Bone in Breast Cancer Patients
2010
Endocrine Therapy for Hormone Receptor–Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline
2016
Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management
2016
Precision glycocalyx editing as a strategy for cancer immunotherapy
2016 StandoutNobel
Reactive Oxygen Species (ROS)-Based Nanomedicine
2019 Standout
Hypoxia-inducible factor 1-dependent expression of platelet-derived growth factor B promotes lymphatic metastasis of hypoxic breast cancer cells
2012 StandoutNobel
Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer
2015
T cell exclusion, immune privilege, and the tumor microenvironment
2015 StandoutScience
NCCN Task Force Report: Adjuvant Therapy for Breast Cancer
2006
Meeting Highlights: Updated International Expert Consensus on the Primary Therapy of Early Breast Cancer
2003
Rational Design of Bisphosphonate Lipid-like Materials for mRNA Delivery to the Bone Microenvironment
2022 StandoutNobel
Chemoendocrine Therapy for Premenopausal Women With Axillary Lymph Node–Positive, Steroid Hormone Receptor–Positive Breast Cancer: Results From INT 0101 (E5188)
2005
Hypoxia-inducible factor-dependent signaling between triple-negative breast cancer cells and mesenchymal stem cells promotes macrophage recruitment
2014 StandoutNobel
Reactive oxygen species generating systems meeting challenges of photodynamic cancer therapy
2016 Standout
Metastatic Behavior of Breast Cancer Subtypes
2010 Standout
Adjuvant Capecitabine, Docetaxel, Cyclophosphamide, and Epirubicin for Early Breast Cancer: Final Analysis of the Randomized FinXX Trial
2011
Works of Brigitte Mlineritsch being referenced
Phase II Study of Single-Agent Pegylated Liposomal Doxorubicin HCl (PLD) in Metastatic Breast Cancer After First-Line Treatment Failure
2004
Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial
2019
Hypertension as a predictive marker for bevacizumab in metastatic breast cancer: results from a retrospective matched-pair analysis.
2014
Significant Increase in Breast Conservation in 16 Years of Trials Conducted by the Austrian Breast & Colorectal Cancer Study Group
2003
Randomized Trial of Low-Dose Chemotherapy Added to Tamoxifen in Patients With Receptor-Positive and Lymph Node–Positive Breast Cancer
1999
Fulvestrant (‘Faslodex’) in heavily pretreated postmenopausal patients with advanced breast cancer: single centre clinical experience from the compassionate use programme
2007
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial
2011
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy
2008
The predictive impact of body mass index on the efficacy of extended adjuvant endocrine treatment with anastrozole in postmenopausal patients with breast cancer: an analysis of the randomised ABCSG-6a trial
2013
Extended Adjuvant Therapy With Anastrozole Among Postmenopausal Breast Cancer Patients: Results From the Randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a
2007
4BA A randomized phase III study comparing epirubicin, docetaxel, and capecitabine (EDC) to epirubicin and docetaxel (ED) as neoadjuvant treatment for early breast cancer – first results of the Austrian Breast and Colorectal Cancer Study Group-Trial 24 (ABCSG-24)
2009
Zoledronic Acid Prevents Cancer Treatment–Induced Bone Loss in Premenopausal Women Receiving Adjuvant Endocrine Therapy for Hormone-Responsive Breast Cancer: A Report From the Austrian Breast and Colorectal Cancer Study Group
2006
Impact of pretreatment thrombocytosis on survival in primary breast cancer
2003
Extended adjuvant treatment with anastrozole: Results from the Austrian Breast and Colorectal Cancer Study Group Trial 6a (ABCSG-6a)
2005
S1-2: Long-Term Follow-Up in ABCSG-12: Significantly Improved Overall Survival with Adjuvant Zoledronic Acid in Premenopausal Patients with Endocrine-Receptor–Positive Early Breast Cancer.
2011
Randomized Trial of Tamoxifen Versus Tamoxifen Plus Aminoglutethimide as Adjuvant Treatment in Postmenopausal Breast Cancer Patients With Hormone Receptor-Positive Disease: Austrian Breast and Colorectal Cancer Study Group Trial 6
2003
Pathologic Complete Response With Six Compared With Three Cycles of Neoadjuvant Epirubicin Plus Docetaxel and Granulocyte Colony-Stimulating Factor in Operable Breast Cancer: Results of ABCSG-14
2007
Pathologic complete response (pCR) in patient subgroups: An analysis of ABCSG-24, a phase III, randomized study of anthracycline- and taxane-based neoadjuvant therapy with or without capecitabine in early breast cancer (EBC).
2010
Overall survival with adjuvant zoledronic acid in patients with premenopausal breast cancer with complete endocrine blockade: Long-term results from ABCSG-12.
2011
Randomized Adjuvant Trial of Tamoxifen and Goserelin Versus Cyclophosphamide, Methotrexate, and Fluorouracil: Evidence for the Superiority of Treatment With Endocrine Blockade in Premenopausal Patients With Hormone-Responsive Breast Cancer—Austrian Breast and Colorectal Cancer Study Group Trial 5
2002